Hostname: page-component-76fb5796d-45l2p Total loading time: 0 Render date: 2024-04-27T01:39:45.036Z Has data issue: false hasContentIssue false
  • English
  • Français

Antipsychotics in dementia: are they being appropriately prescribed?

Published online by Cambridge University Press:  13 January 2010

Fozia Roked ,
Asha Omar ,
Fayaz Roked ,
Ridwan Ahmed  and
Abdul Patel
Fozia Roked
Affiliation:
University of Birmingham, Edgbaston, Birmingham, U.K.
Asha Omar
Affiliation:
University of Birmingham, Edgbaston, Birmingham, U.K.
Fayaz Roked
Affiliation:
Hammersmith Hospital, Du Cane Road, London, U.K.
Ridwan Ahmed
Affiliation:
The Barberry National Centre for Mental Health, Edgbaston, Birmingham, U.K. Email: abdul.patel@bsmht.nhs.uk
Abdul Patel
Affiliation:
The Barberry National Centre for Mental Health, Edgbaston, Birmingham, U.K. Email: abdul.patel@bsmht.nhs.uk
Rights & Permissions [Opens in a new window]

Extract

In 2007, the U.K.'s All-Party Parliamentary Group on Dementia (APPG) undertook an inquiry into the prescription of antipsychotics for people with dementia on account of concerns expressed by carers, patient organizations and academics about the appropriateness and safety of these drugs (All-Party Parliamentary Group on Dementia, 2008). It has been estimated that 32% of patients with dementia in care homes are prescribed antipsychotics (Alldred et al., 2007). Both typical and atypical antipsychotics are associated with QT prolongation, which can lead to arrhythmias and sudden death (Joint Formulary Committee, 2009). They are also associated with an increased risk of cerebrovascular events. Adverse effects in the elderly include excessive sedation and dizziness, which can lead to falls and therefore accelerated cognitive decline.

Type
Letters
Information
International Psychogeriatrics , Volume 22 , Issue 3 , May 2010 , pp. 501 - 502
Copyright
Copyright © International Psychogeriatric Association 2010

In 2007, the U.K.'s All-Party Parliamentary Group on Dementia (APPG) undertook an inquiry into the prescription of antipsychotics for people with dementia on account of concerns expressed by carers, patient organizations and academics about the appropriateness and safety of these drugs (All-Party Parliamentary Group on Dementia, 2008). It has been estimated that 32% of patients with dementia in care homes are prescribed antipsychotics (Alldred et al., Reference Alldred2007). Both typical and atypical antipsychotics are associated with QT prolongation, which can lead to arrhythmias and sudden death (Joint Formulary Committee, 2009). They are also associated with an increased risk of cerebrovascular events. Adverse effects in the elderly include excessive sedation and dizziness, which can lead to falls and therefore accelerated cognitive decline.

Behavioral and psychological symptoms (BPSD) are common in dementia, occurring in up to 80% of cases (Ballard et al., Reference Ballard2008). They include agitation, aggression, delusions, hallucinations, disinhibition, irritability and aberrant motor behavior.

NICE guidelines state that antipsychotics should only be considered for severe or agitated behavior causing significant distress or if there is immediate risk of harm to self or others (National Institute for Health and Clinical Excellence, 2006). It is therefore pertinent to discuss the anticipated use of these drugs with patients and their carers. Target symptoms should be identified and documented and the subsequent change in these symptoms should be assessed and recorded regularly. Treatment with antipsychotics should be time-limited and reviewed every three months or according to clinical need. In 2008, the APPG acknowledged the excessive prescription of antipsychotics and stressed the importance of adhering to NICE guidelines regarding the prescription of antipsychotics. They also highlighted the need to audit the prescription of antipsychotics in patients with dementia.

We identified patients referred to an Old Age Psychiatric team based at The Queen Elizabeth Psychiatric Hospital in Birmingham, U.K., using medical and electronic records. All patients seen between August 2005 and August 2007 who received a DSM-IV (American Psychiatric Association, 1994) diagnosis of dementia were included in our audit. Medical notes were reviewed to obtain: age; gender; type of dementia; MMSE score; presenting symptoms; presence of BPSD; treatment offered, including antipsychotics; duration of pharmacological treatment; mean follow-up.

Seventy patients were identified. The study population comprised 27 men and 43 women, with a median age of 76 years. Thirteen (18.6%) patients had mild cognitive impairment, 51 (72.9%) moderate cognitive impairment and 6 (8.6%) severe cognitive impairment. Fifty (71.4%) had BPSD and antipsychotic medication was prescribed in 14 (28.0%) of these. Of these 14, 11 (78.6%) received typical antipsychotics and 3 (21.4%) atypical antipsychotics.

Of the 14 patients prescribed antipsychotics, six (42.9%) were prescribed these drugs for less than three months, three (21.4%) for three to six months, and five (35.7%) for more than six months. The maximum period for which any patient took antipsychotics was eight months. The remaining 36 patients with BPSD were not prescribed antipsychotics.

A significant number of patients with dementia who were seen by this Old Age Psychiatric service presented with BPSD. The majority of these were not treated with antipsychotics. This Old Age Psychiatric team is adhering to NICE guidelines: namely, the use of antipsychotics is limited to patients with severe BPSD, and antipsychotics are prescribed to most patients for a limited period of time.

From our audit findings we believe that clinicians would benefit from adopting the following guidance:

  • • The risks and benefits of prescribing antipsychotics should be reviewed prior to prescribing antipsychotics in patients with dementia.

  • • Teams should document the BPSD for which antipsychotics are prescribed.

  • • Teams should document discussions with patients and their carers about antipsychotic prescriptions.

  • • A flagging system should be introduced to remind clinicians to review antipsychotic prescriptions and symptoms in patients with dementia every three months.

  • • Clinical teams should regularly audit their prescribing of antipsychotics in patients with dementia.

Whilst there is much evidence regarding the potential adverse effects of antipsychotics, their benefit in relieving symptoms in patients with dementia is also clear. The findings of the APPG have highlighted the need for regulatory processes to ensure these drugs are used in an appropriate and safe manner and audit is a simple and effective means of achieving this.

Conflict of interest declaration

AP is the consultant of the Old Age Psychiatric team whose performance we audited.

References

All-Party Parliamentary Group on Dementia (2008). Always a Last Resort. Inquiry into the Prescription of Antipsychotic Drugs to People with Dementia Living in Care Homes. London: Alzheimer's Society.Google Scholar
Alldred, D. P. et al. (2007). Antipsychotic prescribing patterns in care homes and relationship with dementia. Psychiatric Bulletin, 31, 329–332.Google Scholar
American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders, 4th edn.Washington, DC: American Psychiatric Association.Google Scholar
Ballard, C. et al. (2008). Neuropsychiatric symptoms in dementia: importance and treatment considerations. International Review of Psychiatry, 20, 396–404.CrossRefGoogle ScholarPubMed
Joint Formulary Committee (2009). British National Formulary, 57th edn.London: British Medical Association and Royal Pharmaceutical Society of Great Britain.Google Scholar
National Institute for Health and Clinical Excellence (2006). Dementia: Supporting People with Dementia and their Carers in Health and Social Care. Available at: http://www.nice.org.uk/nicemedia/pdf/CG042NICEGuideline.pdf.Google Scholar